# Durga Kanigicherla

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/durga-kanigicherla/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,378 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 13 |
| i10-index | 18 |
| Last Known Institution | Manchester Academic Health Science Centre |
| OpenAlex ID | https://openalex.org/A5037367145 |
| ORCID iD | 0000-0003-3011-7878 |
| Works | 67 |

## Researcher papers

- [Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy](https://scholariq.org/papers/anti-pla2r-antibodies-measured-by-elisa-predict-long-term-outcome-in-a-prevalent/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Thromboembolism in nephrotic syndrome: controversies and uncertainties](https://scholariq.org/papers/thromboembolism-in-nephrotic-syndrome-controversies-and-uncertainties/)
- [Long-term outcomes of persistent disease and relapse in primary membranous nephropathy](https://scholariq.org/papers/long-term-outcomes-of-persistent-disease-and-relapse-in-primary-membranous/)
- [Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model](https://scholariq.org/papers/rituximab-versus-the-modified-ponticelli-regimen-in-the-treatment-of-primary/)
- [Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection](https://scholariq.org/papers/anti-thymocyte-globulin-for-treatment-of-t-cell-mediated-allograft-rejection/)
- [Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New‐incident and relapsing primary membranous nephropathy](https://scholariq.org/papers/intravenous-pulse-cyclophosphamide-and-steroids-induce-immunological-and/)
- [Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?](https://scholariq.org/papers/can-use-of-the-serum-anti-pla2r-antibody-negate-the-need-for-a-renal-biopsy-in/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Manchester Academic Health Science Centre](https://scholariq.org/institutions/manchester-academic-health-science-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.